Table 2 Demographics based on SGLT2i class.

Total T2D patients on SGLT2i

N, %

14

7280

2646

Prevalence of total DKA

N, %

3/14 (0.21%)

31/7280 (0.43%)

9/2646 (0.34%)

Prevalence of EuDKA

N, %

3/14 (0.21%)

15/7280 (0.21%)

7/2646 (0.26%)

Prevalence of hDKA

N, %

0

16/7280 (0.23%)

2/2646 (0.08%)

Males

N

1

15

3

Females

N

2

16

6

Ethnicities

N

MENA

2

23

7

Southeast Asia

1

4

1

Others

0

4

1

Triggers:

N

Gastroenteritis

1

8

2

Psychiatric disorder

0

2

0

Pancreatitis

0

2

0

Surgery

0

0

1

Insulin non-compliance

0

3

1

Infections

2

10

2

Diabetes complications

N

Retinopathy

0

4

2

Nephropathy

1

4

2

Diabetic foot

0

0

2

Amputation

0

0

1

Peripheral arterial disease

0

0

2

Co-morbidities

N

Coronary artery disease

1

5

2

Heart failure

2

1

1

Asthma

0

8

3

Chronic liver disease

0

1

0

Hypertension

1

19

3

Malignancy

0

1

1

Insulin use

N

3

20

6

Sulfonylurea

N

2

10

3

Metformin

N

1

21

6

Thiazolidinediones

N

0

10

5

Meglitinides

N

0

1

1

Alpha-glucosidase inhibitor

N

0

1

0

GLP-1 agonist

N

1

3

1

DPP-4 inhibitors

N

0

12

5

Inhaled steroids

N

0

8

3

In-hospital Mortality

N

0

1

0

MICU admission

N

2

14

3

HbA1c

mmol/mol

96.7

79.2

72.7

HbA1c, Median (IQR)

Percentage

11 (11–11.6)

9.4 (7.95–11.5)

8.8 (8.7–10.6)

Admission Glucose, Median (IQR)

mmol/L

9.6 (8.25–9.6)

14.4 (10.3–22.4)

12.2 (10.8–13.7)

pH, Median (IQR)

NA

7.17 (7.17- 7.22)

7.21 (7.21 -7.31)

7.29 (7.29—7.34)

Anion gap, Median (IQR)

mEq/L

25.5 (21.8–26.8)

19 (17.5–21.3)

20 (17–23)

Length of stay, Median (IQR)

Days

4 (3–4.5)

5 (3–9)

9 (2–16)

DKA duration, Median (IQR)

Days

2 (2–2.5)

3 (2–4)

2 (2–3)